Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 3, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Trevi Therapeutics, Inc. is a Delaware corporation with its principal executive offices in New Haven, Connecticut.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance results.
Material Changes and Corporate Actions
- Stock Incentive Plan Amendment: Stockholders approved the Amended and Restated 2019 Stock Incentive Plan. Key changes include an increase of 8,000,000 shares available for issuance, limitations on non-employee director compensation, and a prohibition on liberal share recycling (shares used for exercise or tax withholding will not be re-added to the plan).
- Authorized Share Increase: Stockholders approved an amendment to the Restated Certificate of Incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares. This amendment became effective upon filing with the Delaware Secretary of State on June 3, 2026.
- Board Election: Michael Heffernan was elected as a Class I director for a term expiring at the 2029 annual meeting.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
Stockholders voted on five proposals at the Annual Meeting. All proposals were approved with significant majorities:
- Director Election (Michael Heffernan): 81,567,765 For; 18,635,726 Withheld.
- Auditor Ratification: 114,001,970 For; 223,323 Against.
- Executive Compensation (Say-on-Pay): 98,119,461 For; 1,982,126 Against.
- Stock Incentive Plan Approval: 98,140,470 For; 1,961,030 Against.
- Authorized Share Increase: 110,453,620 For; 3,872,599 Against.
The filing does not contain specific management commentary regarding future outlook, risks, or contingencies beyond the standard incorporation of the proxy statement and plan details.
Investor Verification Checklist
- Verify the impact of the 8,000,000 share increase on potential future dilution.
- Review the full text of the Amended and Restated 2019 Stock Incentive Plan (Exhibit 99.1) for specific vesting and forfeiture terms.
- Confirm the effective date of the authorized share increase (June 3, 2026) and its implications for future capital raises.
- Check the definitive proxy statement filed on April 21, 2026, for detailed background on the director election and compensation proposals.